FDAnews
www.fdanews.com/articles/178958-collplant-gets-ce-mark-for-vergenix-str-for-treatment-of-tendinopathy

CollPlant Gets CE Mark for Vergenix STR for Treatment of Tendinopathy

October 19, 2016

Collplant has received the CE Mark for Vergenix STR, which is a soft tissue repair matrix for the treatment of tendinopathy.

The device is primarily made of cross-linked rhCollagen designed to be combined with platelet-rich plasma (PRP), a concentrated blood plasma derived from the patient's own blood that contains high levels of platelets, which are critical to the healing process.

The matrix formed will then have the ability to release growth factors in a controlled manner and with controlled biodegradation time, initiating tissue repair.

Sales in Europe are expected to commence in the coming months. — Cynthia Jessup

View today's stories